BDBM185309 US10011588, Example 129::US10689373, Example 129::US9156829, 128::US9156829, 129

SMILES FC(F)(F)c1ccc(NC2CC(F)(F)CC2NC(=O)c2ccccc2-n2nccn2)nc1

InChI Key InChIKey=KDDGILRGTBBNDE-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 185309   

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 33nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 633nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 1.00E+4nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 8.75E+3nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 33nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 633nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 8.75E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 33nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 633nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185309(US9156829, 129 | US9156829, 128 | US10011588, Exam...)
Affinity DataIC50: 8.75E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent